Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Viridian Therapeutics submits IND application for VRDN-001 » 08:07
10/14/21
10/14
08:07
10/14/21
08:07
VRDN

Viridian Therapeutics

$16.48 /

+0.48 (+3.00%)

Viridian Therapeutics…

Viridian Therapeutics announced the submission of an investigational new drug application to the United States Food and Drug Administration. The Company is seeking authorization to initiate a Phase 1/2 clinical trial of VRDN-001, an anti-insulin-like growth factor-1 receptor monoclonal antibody in development for the treatment of thyroid eye disease, a debilitating disease that can cause proptosis (bulging eyes), double vision, and potential blindness. The Company believes this clinical trial could provide key proof of concept clinical data in TED patients, with the potential to show clinically meaningful improvements in signs and symptoms of TED, including proptosis. The Company expects to announce top line clinical data from the proof of concept portion of the proposed trial in the second quarter of 2022.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$16.48 /

+0.48 (+3.00%)

VRDN Viridian Therapeutics
$16.48 /

+0.48 (+3.00%)

10/12/21 Evercore ISI
Evercore starts Viridian at Outperform on thyroid eye disease opportunity
10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$16.48 /

+0.48 (+3.00%)

  • 21
    Sep
VRDN Viridian Therapeutics
$16.48 /

+0.48 (+3.00%)

VRDN Viridian Therapeutics
$16.48 /

+0.48 (+3.00%)

Initiation
Evercore starts Viridian at Outperform on thyroid eye disease opportunity » 06:56
10/12/21
10/12
06:56
10/12/21
06:56
VRDN

Viridian Therapeutics

$15.71 /

-0.5 (-3.08%)

, HZNP

Horizon Therapeutics

$113.26 /

-0.48 (-0.42%)

Evercore ISI analyst…

Evercore ISI analyst Maneka Mirchandaney initiated coverage of Viridian Therapeutics (VRDN) with an Outperform rating and $40 price target. The rare disease company is currently focused on developing IGF-1R antibodies for thyroid eye disease, or TED, said Mirchandaney. The analyst notes that Horizon Therapeutics' (HZNP) Tepezza acts on the same pathway and "provides strong validation on efficacy and commercial potential" for Viridian's "potentially best-in-class IGF-1R antibodies."

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

HZNP Horizon Therapeutics
$113.26 /

-0.48 (-0.42%)

VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

10/12/21 Evercore ISI
Viridian Therapeutics initiated with an Outperform at Evercore ISI
01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
HZNP Horizon Therapeutics
$113.26 /

-0.48 (-0.42%)

10/06/21 Jefferies
Horizon Therapeutics assumed with a Buy at Jefferies
10/06/21 William Blair
Acer Therapeutics set up for 'major event' with NDA accepted, says William Blair
09/30/21 Piper Sandler
Horizon well positioned for further multiple expansion, says Piper Sandler
08/19/21 SVB Leerink
Amryt Pharma initiated with an Outperform at SVB Leerink
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

HZNP Horizon Therapeutics
$113.26 /

-0.48 (-0.42%)

  • 21
    Sep
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

Initiation
Viridian Therapeutics initiated with an Outperform at Evercore ISI » 06:43
10/12/21
10/12
06:43
10/12/21
06:43
VRDN

Viridian Therapeutics

$15.71 /

-0.5 (-3.08%)

Evercore ISI analyst…

Evercore ISI analyst Maneka Mirchandaney initiated coverage of Viridian Therapeutics with an Outperform rating and $40 price target.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

  • 21
    Sep
VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

VRDN Viridian Therapeutics
$15.71 /

-0.5 (-3.08%)

Over a month ago
Options
Eleven new option listings and one option delisting on September 22nd » 08:30
09/22/21
09/22
08:30
09/22/21
08:30
PMCB

PharmaCyte Biotech

$3.47 /

+0.155 (+4.68%)

, SBOW

SilverBow Resources

$19.06 /

-0.88 (-4.41%)

, SELF

Global Self Storage

$5.07 /

-0.2 (-3.80%)

, USAP

Universal Stainless & Alloy

$10.63 /

+0.33 (+3.20%)

, TWKS

Thoughtworks

$30.50 /

-1.84 (-5.69%)

, VRDN

Viridian Therapeutics

$12.65 /

+1.45 (+12.95%)

, SRAD

Sportradar

$26.01 /

-0.29 (-1.10%)

, SVBI

Severn Bancorp, Inc.

$12.16 /

+0.01 (+0.08%)

, SNR

New Senior Investment

$8.82 /

+ (+0.00%)

New option listings for…

New option listings for September 22nd include PharmaCyte Biotech Inc (PMCB), ProShares Ultra MSCI Brazil Capped (UBR), Cambria Cannabis ETF (TOKE), SilverBow Resorces (SBOW), First Trust SMID Cap Rising Dividend Achievers (SDVY), Self Storage Group (SELF), Universal Stainless & Alloy (USAP), TWKS Stock (TWKS), Viridian Therapeutics Inc (VRDN), SRAD Stock (SRAD), and Severn Bancorp, Inc. (SVBI). Option delistings effective September 22nd include New Senior Investment (SNR).

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$12.65 /

+1.45 (+12.95%)

USAP Universal Stainless & Alloy
$10.63 /

+0.33 (+3.20%)

SRAD Sportradar
$26.01 /

-0.29 (-1.10%)

SNR New Senior Investment
$8.82 /

+ (+0.00%)

SBOW SilverBow Resources
$19.06 /

-0.88 (-4.41%)

PMCB PharmaCyte Biotech
$3.47 /

+0.155 (+4.68%)

PMCB PharmaCyte Biotech
$3.47 /

+0.155 (+4.68%)

SBOW SilverBow Resources
$19.06 /

-0.88 (-4.41%)

09/08/21 Truist
Truist upgrades SilverBow Resources to Buy on production growth, solid prices
09/08/21 Truist
SilverBow Resources upgraded to Buy from Hold at Truist
07/01/21 Truist
SilverBow Resources price target raised to $22 from $12 at Truist
SELF Global Self Storage
$5.07 /

-0.2 (-3.80%)

04/22/21 Aegis
Global Self Storage initiated with a Buy at Aegis
USAP Universal Stainless & Alloy
$10.63 /

+0.33 (+3.20%)

TWKS Thoughtworks
$30.50 /

-1.84 (-5.69%)

VRDN Viridian Therapeutics
$12.65 /

+1.45 (+12.95%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
SRAD Sportradar
$26.01 /

-0.29 (-1.10%)

SVBI Severn Bancorp, Inc.
$12.16 /

+0.01 (+0.08%)

03/08/21 Keefe Bruyette
Shore Bancshares upgraded to Outperform from Market Perform at Keefe Bruyette
SNR New Senior Investment
$8.82 /

+ (+0.00%)

07/01/21 BofA
Ventas downgraded to Neutral from Buy at BofA
07/01/21 BTIG
New Senior Investment downgraded to Neutral from Buy at BTIG
06/30/21 RBC Capital
Ventas price target raised to $65 from $62 at RBC Capital
06/30/21 Colliers
New Senior Investment downgraded to Neutral from Buy at Colliers
VRDN Viridian Therapeutics
$12.65 /

+1.45 (+12.95%)

USAP Universal Stainless & Alloy
$10.63 /

+0.33 (+3.20%)

SNR New Senior Investment
$8.82 /

+ (+0.00%)

  • 21
    Sep
  • 15
    Sep
  • 14
    Sep
  • 23
    Jun
SRAD Sportradar
$26.01 /

-0.29 (-1.10%)

VRDN Viridian Therapeutics
$12.65 /

+1.45 (+12.95%)

TWKS Thoughtworks
$30.50 /

-1.84 (-5.69%)

SRAD Sportradar
$26.01 /

-0.29 (-1.10%)

SNR New Senior Investment
$8.82 /

+ (+0.00%)

SELF Global Self Storage
$5.07 /

-0.2 (-3.80%)

PMCB PharmaCyte Biotech
$3.47 /

+0.155 (+4.68%)

Syndicate
Viridian Therapeutics 6.185M share Spot Secondary priced at $11.00 » 06:05
09/21/21
09/21
06:05
09/21/21
06:05
VRDN

Viridian Therapeutics

$10.52 /

-1.11 (-9.54%)

Jefferies, SVB Leerink…

Jefferies, SVB Leerink and Evercore ISI acted as joint book running managers for the offering.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

  • 21
    Sep
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

On The Fly
Fly Intel: After-Hours Movers » 18:39
09/20/21
09/20
18:39
09/20/21
18:39
APRE

Aprea Therapeutics

$4.84 /

-0.275 (-5.38%)

, VRDN

Viridian Therapeutics

$10.52 /

-1.11 (-9.54%)

, GMAB

Genmab

$42.88 /

-0.16 (-0.37%)

, SGEN

Seagen

$159.09 /

+2.8 (+1.79%)

, SDC

SmileDirectClub

$6.48 /

-0.22 (-3.28%)

, HRI

Herc Holdings

$125.41 /

-4.1 (-3.17%)

, HLF

Herbalife Nutrition

$44.12 /

-0.285 (-0.64%)

, LEN

Lennar

$98.16 /

-3.17 (-3.13%)

, VRCA

Verrica Pharmaceuticals

$12.01 /

-0.045 (-0.37%)

, ROLL

RBC Bearings

$215.67 /

+2.62 (+1.23%)

, CFMS

Conformis

$1.70 /

-0.135 (-7.38%)

, KAR

KAR Auction

$15.73 /

-0.38 (-2.36%)

, PGR

Progressive

$92.21 /

-0.42 (-0.45%)

Check out this evening's…

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SGEN Seagen
$159.09 /

+2.8 (+1.79%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

08/20/21 JPMorgan
JPMorgan downgrades Aprea to Underweight on 'multiple overhangs'
08/20/21 JPMorgan
Aprea Therapeutics downgraded to Underweight from Neutral at JPMorgan
08/16/21 Berenberg
Aprea Therapeutics downgraded to Hold from Buy at Berenberg
08/16/21 H.C. Wainwright
Aprea Therapeutics price target lowered to $4 from $6 at H.C. Wainwright
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
GMAB Genmab
$42.88 /

-0.16 (-0.37%)

09/16/21
Fly Intel: Top five analyst downgrades
09/16/21 Jefferies
Genmab downgraded to Hold from Buy at Jefferies
09/07/21
Fly Intel: Top five analyst downgrades
09/07/21 Morgan Stanley
Morgan Stanley cuts Genmab to Underweight amid high investor expectations
SGEN Seagen
$159.09 /

+2.8 (+1.79%)

05/17/21 Evercore ISI
Seagen initiated with an In Line at Evercore ISI
04/30/21 Piper Sandler
Seagen price target lowered to $160 from $170 at Piper Sandler
04/12/21 B. Riley
B. Riley calls Agenus the next Seagen, reiterates $8 target
03/30/21 Credit Suisse
Seagen initiated with a Neutral at Credit Suisse
SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

09/20/21 Stifel
Stifel cuts SmileDirectClub to Hold on market share loss, growth uncertainty
09/20/21 Stifel
SmileDirectClub downgraded to Hold from Buy at Stifel
08/13/21
Fly Intel: Top five analyst downgrades
08/13/21 Wolfe Research
SmileDirectClub downgraded to Peer Perform from Outperform at Wolfe Research
HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

09/16/21 Baird
Ashtead results positive for United Rentals and Herc, says Baird
07/23/21 Barclays
Herc Holdings price target raised to $135 from $128 at Barclays
07/22/21 Baird
Herc Holdings price target raised to $145 from $135 at Baird
07/14/21 Barclays
Herc Holdings price target raised to $128 from $115 at Barclays
HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

09/16/21 Citi
Herbalife selloff on guidance cut 'distinct overreaction,' says Citi
09/15/21 B. Riley
Herbalife Nutrition price target lowered to $61 from $70 at B. Riley
09/15/21 Jefferies
Herbalife's 20% pullback 'extreme' relative to guide down, says Jefferies
09/14/21 Jefferies
Herbalife Nutrition guidance cut 'a surprise,' says Jefferies
LEN Lennar
$98.16 /

-3.17 (-3.13%)

06/21/21 Argus
Lennar has an edge on many rivals, says Argus
06/18/21
Fly Intel: Top five analyst upgrades
06/18/21 Evercore ISI
Lennar price target raised to $160 from $121 at Evercore ISI
06/18/21 JPMorgan
JPMorgan upgrades Lennar with transformation not reflected in shares
VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

06/17/21 Needham
Verrica Pharmaceuticals's Ycanth offers superior efficacy to Novan, says Needham
06/01/21 Northland
Verrica Pharmaceuticals price target lowered to $19 from $24 at Northland
05/13/21 RBC Capital
Verrica Pharmaceuticals initiated with an Outperform at RBC Capital
03/08/21 H.C. Wainwright
Verrica Pharmaceuticals price target raised to $24 from $21 at H.C. Wainwright
ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

07/27/21 Truist
RBC Bearings price target raised to $225 from $175 at Truist
02/02/21 Truist
RBC Bearings price target raised to $140 from $118 at Truist
01/11/21 Truist
RBC Bearings upgraded to Hold from Sell at Truist
CFMS Conformis
$1.70 /

-0.135 (-7.38%)

03/04/21 Canaccord
Conformis undervalued despite momentum, says Canaccord
KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

08/04/21 JPMorgan
ACV Auctions upgraded to Overweight from Neutral at JPMorgan
05/24/21 JPMorgan
KAR Auction price target raised to $24 from $21 at JPMorgan
05/21/21 BofA
KAR Auction upgraded to Buy from Underperform at BofA
02/18/21
Fly Intel: Top five analyst downgrades
PGR Progressive
$92.21 /

-0.42 (-0.45%)

08/17/21 Evercore ISI
Progressive added to 'Tactical Underperform List' at Evercore ISI
08/16/21 Wolfe Research
Progressive initiated with an Underperform at Wolfe Research
07/16/21 Barclays
Progressive price target lowered to $84 from $86 at Barclays
07/09/21 BofA
Progressive added to US 1 List; Arch Capital removed at BofA
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SGEN Seagen
$159.09 /

+2.8 (+1.79%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HRI Herc Holdings
$125.41 /

-4.1 (-3.17%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

  • 22
    Sep
  • 21
    Sep
  • 23
    Mar
  • 12
    Feb
  • 24
    Nov
  • 19
    Nov
  • 24
    Sep
SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

ROLL RBC Bearings
$215.67 /

+2.62 (+1.23%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

HLF Herbalife Nutrition
$44.12 /

-0.285 (-0.64%)

GMAB Genmab
$42.88 /

-0.16 (-0.37%)

CFMS Conformis
$1.70 /

-0.135 (-7.38%)

VRCA Verrica Pharmaceuticals
$12.01 /

-0.045 (-0.37%)

SDC SmileDirectClub
$6.48 /

-0.22 (-3.28%)

PGR Progressive
$92.21 /

-0.42 (-0.45%)

LEN Lennar
$98.16 /

-3.17 (-3.13%)

KAR KAR Auction
$15.73 /

-0.38 (-2.36%)

APRE Aprea Therapeutics
$4.84 /

-0.275 (-5.38%)

Syndicate
Viridian Therapeutics files to sell common stock and preferred stock » 16:04
09/20/21
09/20
16:04
09/20/21
16:04
VRDN

Viridian Therapeutics

$10.52 /

-1.11 (-9.54%)

Jefferies, SVB Leerink…

Jefferies, SVB Leerink and Evercore ISI are acting as joint book-running managers for the offering.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$10.52 /

-1.11 (-9.54%)

Hot Stocks
Viridian Therapeutics provides updates on upcoming milestones » 07:05
08/11/21
08/11
07:05
08/11/21
07:05
VRDN

Viridian Therapeutics

$14.18 /

+0.18 (+1.29%)

VRDN-001: The company…

VRDN-001: The company remains on track to file an IND in the fourth quarter of 2021, with initial proof of concept clinical data in TED patients expected in the second quarter of 2022. VRDN-002: IND-enabling activities remain on track with plans to file an IND by the end of 2021. The Company expects to initiate clinical development with a Phase 1 single ascending dose trial to explore safety, tolerability, pharmacokinetics, and target engagement of intravenous VRDN-002 in healthy volunteers. Data from this trial are expected by mid-year 2022, and could demonstrate feasibility of a low-volume and/or low-frequency dosing paradigm. In parallel, formulation development is on track to support initiation of a clinical trial evaluating low-volume subcutaneous injection of VRDN-002 in 2022. Discovery Pipeline: The Company continues to evaluate additional opportunities to expand its product pipeline for rare disease indications and remains focused on opportunities to leverage validated mechanisms and technologies to bring new therapeutic options to patients underserved by current therapies.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

Hot Stocks
Viridian Therapeutics sees cash, cash equivalents fund operations into 2024 » 07:05
08/11/21
08/11
07:05
08/11/21
07:05
VRDN

Viridian Therapeutics

$14.18 /

+0.18 (+1.29%)

Cash, cash equivalents…

Cash, cash equivalents and short-term investments were $109.3M as of June 30, 2021, compared to $127.6M as of December 31, 2020. The Company believes that its current cash, cash equivalents and short-term investments will be sufficient to fund its operations into 2024.

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies
VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

Earnings
Viridian Therapeutics reports Q2 EPS ($2.21), consensus ($1.52) » 07:05
08/11/21
08/11
07:05
08/11/21
07:05
VRDN

Viridian Therapeutics

$14.18 /

+0.18 (+1.29%)

Reports Q2 revenue…

Reports Q2 revenue $1.090M. "We continue to make rapid progress with our lead TED program, VRDN-001," said Jonathan Violin, Ph.D., President and Chief Executive Officer of Viridian. "Following a highly collaborative pre-IND dialogue with the FDA for VRDN-001, we remain on track to submit IND filings for both VRDN-001 and VRDN-002 to the FDA in the fourth quarter of 2021. This would put us on track to report key Phase 1/ 2 proof of concept clinical data in TED patients in the second quarter of 2022 for VRDN-001, quickly followed by Phase 1 first-in-human data in mid-year 2022 for VRDN-002. We are also progressing our discovery programs as we expand our pipeline beyond IGF-1R and TED, advancing our strategy to discover and develop novel and differentiated monoclonal antibodies."

ShowHide Related Items >><<
VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

VRDN Viridian Therapeutics
$14.18 /

+0.18 (+1.29%)

01/25/21 Ladenburg
Viridian Therapeutics initiated with a Buy at Ladenburg
01/20/21 Jefferies
Viridian Therapeutics price target raised to $28 on assumption at Jefferies

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.